A Nano-Strategy for Advanced Triple-Negative Breast Cancer Therapy by Regulating Intratumoral Microbiota DOI
Jifan Gao, Lu Tang,

Cong Fu

et al.

Nano Letters, Journal Year: 2025, Volume and Issue: unknown

Published: April 3, 2025

Intratumoral microbiota have been identified as a component of the tumor microenvironment that regulates metastatic behavior tumors. They serve not only indicators pathology but also potential drug targets in cancer therapy. Herein, multifunctional nanoplatform (DD@FEL) is prepared by combining antibiotic doxycycline (DOXY) can combat intratumoral and chemotherapeutic doxorubicin (DOX) ergosterol-originated liposome. Specially, ergosterol utilized substitute for cholesterol liposomes to exert pharmacological activity. Mechanistically, DD@FEL leveraged DOXY inhibit metastasis based on regulation microbiota, which synergizes with effect DOX, eventually inhibiting progression triple-negative breast (TNBC). Verified both vitro vivo, effectively exerts cytotoxic TNBC cells, delays growth primary TNBC, attenuates development its lung metastasis, providing promising therapeutic strategy control orthotopic TNBC.

Language: Английский

mRNA therapy: A new frontier in regenerative medicine DOI Creative Commons
Danna Xue, Yue Zhang,

Anran Shen

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Abstract Tissue regeneration has raised intensive attention due to its great significance in overcoming various diseases resulting from different injuries. Since the COVID‐19 pandemic, mRNA therapeutics have emerged as innovative strategies prevention and treatment of their unique advantages. Compared traditional regenerative strategies, therapy offers rapid translation into proteins with low production cost high modifiability. Herein, we discuss progress key processes therapy, focusing on therapeutic modification delivery carriers. The preclinical clinical studies for cardiac, lung, liver, kidney, locomotor system, skin lesions neurological disorders were summarized comprehensively. Developing reduce immunogenicity off‐target effects, well optimization system may accelerate pace translation.

Language: Английский

Citations

0
Applications of mRNA Delivery in Cancer Immunotherapy DOI Creative Commons
Xiaoyu Pan,

Yang-Wen-Qing Zhang,

Caixia Dai

et al.

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 3339 - 3361

Published: March 1, 2025

Cancer treatment is continually advancing, with immunotherapy gaining prominence as a standard modality that has markedly improved the management of various malignancies. Despite these advancements, efficacy remains variable, certain cancers exhibiting limited response and patient outcomes differing considerably. Thus, enhancing effectiveness imperative. A promising avenue mRNA delivery, employing carriers such liposomes, peptide nanoparticles, inorganic exosomes to introduce cargos encoding tumor antigens, immune-stimulatory, or immune-modulatory molecules into immune microenvironment (TIME). This method aims activate system target eradicate cells. In this review, we characteristics limitations summarize application mechanisms currently prevalent in mRNA-based treatment. Additionally, given significant clinical checkpoint inhibitors (ICIs) chimeric antigen receptor (CAR)-based cell therapies solid tumors (including melanoma, non-small-cell lung cancer, head neck squamous carcinoma, triple-negative breast gastric cancer) leukemia, which have become first-line treatments, highlight discuss recent progress combining delivery ICIs, CAR-T, CAR-NK, CAR-macrophage therapies. combination enhances targeting capabilities ICIs CAR-cell-based therapies, while also mitigating long-term off-target toxicities associated conventional methods. Finally, analyze current systems, nuclease-induced instability, immunogenicity risks, complex carrier production, knowledge gaps concerning dosing safety. Addressing challenges crucial for unlocking potential cancer immunotherapy. Overall, exploring enriches our comprehension holds promise developing personalized effective strategies, potentially responses patients extending their survival time.

Language: Английский

Citations

0
Lipid Nanoparticles for mRNA Delivery in Cancer Immunotherapy DOI
Yasir Alshehry, Xiang Liu,

Wenhua Li

et al.

The AAPS Journal, Journal Year: 2025, Volume and Issue: 27(3)

Published: March 18, 2025

Language: Английский

Citations

0
Emerging strategies in lymph node-targeted nano-delivery systems for tumor immunotherapy DOI Creative Commons
Yang Zhao, Man Tian, Xin Tong

et al.

Essays in Biochemistry, Journal Year: 2025, Volume and Issue: 69(02)

Published: March 28, 2025

The emergence of immunotherapy has led to the clinical approval several related drugs. However, their efficacy against solid tumors remains limited. As hub immune activation, lymph nodes (LNs) play a critical role in tumor by initiating and amplifying responses. Nevertheless, intricate physiological structure barriers within LNs, combined with immunosuppressive microenvironment induced cells, significantly impede therapeutic immunotherapy. Engineered nanoparticles (NPs) have shown great potential overcoming these challenges facilitating targeted drug transport LNs directly or indirectly activating T cells. This review systematically examines structural features key factors influencing targeting efficiency NPs, current strategies for remodeling LNs. Additionally, it discusses future opportunities optimizing NPs enhance immunotherapy, addressing translation safety evaluation.

Language: Английский

Citations

0
A Nano-Strategy for Advanced Triple-Negative Breast Cancer Therapy by Regulating Intratumoral Microbiota DOI
Jifan Gao, Lu Tang,

Cong Fu

et al.

Nano Letters, Journal Year: 2025, Volume and Issue: unknown

Published: April 3, 2025

Intratumoral microbiota have been identified as a component of the tumor microenvironment that regulates metastatic behavior tumors. They serve not only indicators pathology but also potential drug targets in cancer therapy. Herein, multifunctional nanoplatform (DD@FEL) is prepared by combining antibiotic doxycycline (DOXY) can combat intratumoral and chemotherapeutic doxorubicin (DOX) ergosterol-originated liposome. Specially, ergosterol utilized substitute for cholesterol liposomes to exert pharmacological activity. Mechanistically, DD@FEL leveraged DOXY inhibit metastasis based on regulation microbiota, which synergizes with effect DOX, eventually inhibiting progression triple-negative breast (TNBC). Verified both vitro vivo, effectively exerts cytotoxic TNBC cells, delays growth primary TNBC, attenuates development its lung metastasis, providing promising therapeutic strategy control orthotopic TNBC.

Language: Английский

Citations

0